0708 Exploratory Cost-Effectiveness Analysis of TOMAC for Medication-Refractory RLS, Based on Longer-term Clinical Data

Anne Ryschon,Asim Roy,Jan Pietzsch

DOI: https://doi.org/10.1093/sleep/zsae067.0708

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Tonic motor activation (TOMAC) is a non-invasive neuromodulation therapy that provides a non-pharmacologic treatment alternative for patients suffering from medication-refractory restless legs syndrome (RLS). In the current analysis, recently reported longer-term clinical data were used to update prior exploratory cost-effectiveness work. Methods A previously published decision-analytic Markov model was utilized to project outcomes over a lifetime horizon. The cohort and treatment effects modeled were sourced from the extension cohort of the RESTFUL study (mean age 57.6, 43.8% male). Health-related quality of life (EQ-5D utilities) and symptom severity were derived from International RLS Study Group (IRLS) scores reported at baseline and 32-weeks after RESTFUL study entry and compared between the TOMAC (continued TOMAC for 24-weeks following RESTFUL study completion) and control arms. The primary outcome measure was the incremental cost-effectiveness ratio (ICER), measured as the difference in quality-adjusted life years (QALY) gained divided by difference in costs, with costs and resource utilization derived from fee schedules and published data. Cost-effectiveness was evaluated against thresholds of $50,000/$150,000 per QALY, and extensive scenario analyses were performed. Results Study-observed IRLS scores were reduced by -11.3 from baseline to 32 weeks for TOMAC and -5.4 for control. The resulting treatment effect of -5.9 corresponded to a change in utility from 0.82 to 0.87 (0.77 to 0.87 vs. baseline). Over lifetime, TOMAC added 0.73 and 1.44 QALYs (12.98 vs. 12.25 and 12.91 vs.11.47) at incremental costs of $28,066 and $19,072 ($211,704 vs. $183,638 and $212,644 vs. $193,572), resulting in ICERs of $38,685 and $13,251 per QALY gained vs. control and baseline, respectively. TOMAC was found cost-effective or dominant across all tested scenarios, with ICERs ranging from -$29,558 to $48,266 and -$40,684 to $19,564, vs. control and baseline, respectively. Conclusion This updated analysis based on longer-term data confirms earlier findings and suggests TOMAC therapy can provide a high value treatment alternative for patients suffering from medication-refractory RLS. Further increased effect sizes in the longer-term data support assumptions about maintained effect size over time. Support (if any) Wing Tech Inc. received consulting fees from Noctrix Health. AR is an investigator in the RESTFUL study.

neurosciences,clinical neurology